- Home
- / Nurix Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Nurix Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$84 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|
| Revenue | 38.6M | 77.0M | 54.5M | 84.0M |
| General and administrative expense | 38.0M | 42.9M | 45.9M | 52.7M |
| Operating expense total | 222.5M | 232.1M | 267.6M | 369.6M |
| EBIT | (183.9M) | (155.1M) | (213.0M) | (285.7M) |
| EBIT margin, % | -476.0% | -201.4% | -390.5% | -340.2% |
| Interest income | 3.5M | 11.1M | 19.7M | 22.0M |
| Pre tax profit | (180.4M) | (143.9M) | (193.3M) | (263.7M) |
| Income tax expense | 270.0K | 760.0K | ||
| Net Income | (180.4M) | (143.9M) | (193.6M) | (264.5M) |
| EPS | (3.7) | (2.6) | (2.9) | (3.0) |